Volume 61, Issue 3, Pages (March 2002)

Slides:



Advertisements
Similar presentations
Volume 64, Issue 6, Pages (December 2003)
Advertisements

Volume 59, Issue 3, Pages (March 2001)
Volume 61, Issue 4, Pages (April 2002)
Volume 74, Issue 11, Pages (December 2008)
Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-α produced by renal parenchymal cells  B. Zhang, G. Ramesh, C.C. Norbury, W.B. Reeves 
Volume 67, Issue 5, Pages (May 2005)
Volume 70, Issue 1, Pages (July 2006)
Volume 79, Issue 1, Pages (January 2011)
Volume 80, Issue 3, Pages (August 2011)
Y.-H.H. Lien, K.-C. Yong, C. Cho, S. Igarashi, L.-W. Lai 
Renal denervation prevents long-term sequelae of ischemic renal injury
Volume 58, Issue 2, Pages (August 2000)
Pretransplantation assessment of renal viability with NADH fluorimetry
Volume 65, Issue 2, Pages (February 2004)
Volume 64, Issue 5, Pages (November 2003)
Volume 74, Issue 11, Pages (December 2008)
Volume 61, Issue 5, Pages (May 2002)
Volume 64, Issue 6, Pages (December 2003)
Volume 64, Issue 1, Pages (July 2003)
Volume 79, Issue 1, Pages (January 2011)
Volume 70, Issue 2, Pages (July 2006)
Volume 63, Issue 2, Pages (February 2003)
Volume 69, Issue 1, Pages (January 2006)
Decreased renal ischemia–reperfusion injury by IL-16 inactivation
Volume 54, Issue 3, Pages (September 1998)
Gilbert R. Kinsey, Liping Huang, Amy L. Vergis, Li Li, Mark D. Okusa 
Volume 64, Issue 5, Pages (November 2003)
Volume 66, Issue 2, Pages (August 2004)
Volume 58, Issue 3, Pages (September 2000)
Volume 75, Issue 7, Pages (April 2009)
Ischemic and non-ischemic acute kidney injury cause hepatic damage
Volume 55, Issue 2, Pages (February 1999)
Volume 62, Issue 3, Pages (September 2002)
Volume 62, Issue 2, Pages (August 2002)
Volume 54, Issue 3, Pages (September 1998)
Volume 73, Issue 12, Pages (June 2008)
Volume 65, Issue 3, Pages (March 2004)
Volume 85, Issue 1, Pages (January 2014)
Resistance to ischemic acute renal failure in the Brown Norway rat: A new model to study cytoprotection  David P. Basile, Deborah Donohoe, X.I.A. Cao,
Volume 56, Issue 2, Pages (August 1999)
Volume 63, Issue 5, Pages (May 2003)
Volume 61, Issue 4, Pages (April 2002)
Volume 74, Issue 5, Pages (September 2008)
Volume 58, Issue 2, Pages (August 2000)
Volume 67, Issue 5, Pages (May 2005)
Volume 66, Issue 4, Pages (October 2004)
Volume 74, Issue 11, Pages (December 2008)
Role of the T-cell receptor in kidney ischemia–reperfusion injury
Volume 60, Issue 6, Pages (December 2001)
Volume 67, Issue 5, Pages (May 2005)
Volume 71, Issue 6, Pages (March 2007)
Volume 68, Issue 4, Pages (October 2005)
Recapitulation of phylogeny by ontogeny in nephrology
Volume 69, Issue 7, Pages (April 2006)
Volume 64, Issue 3, Pages (September 2003)
Silvia B. Campos, Lucia H.K. Rouch, Antonio C. Seguro 
Volume 57, Issue 2, Pages (October 2000)
Volume 58, Issue 4, Pages (October 2000)
Volume 71, Issue 11, Pages (June 2007)
Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure  D.W. Johnson, B. Pat, D.A. Vesey, Z.
Volume 62, Issue 1, Pages (July 2002)
The more or less ‘pristine’ renal allograft biopsy
Volume 60, Issue 3, Pages (September 2001)
Volume 64, Issue 6, Pages (December 2003)
Effect of prenatal dexamethasone on rat renal development
Volume 74, Issue 8, Pages (October 2008)
A sphingosine-1-phosphate type 1 receptor agonist inhibits the early T-cell transient following renal ischemia–reperfusion injury  L.-W. Lai, K.-C. Yong,
Volume 85, Issue 1, Pages (January 2014)
Transplantation of developing metanephroi into adult rats
Volume 54, Issue 2, Pages (August 1998)
Presentation transcript:

Volume 61, Issue 3, Pages 1064-1078 (March 2002) Propionyl-l-carnitine prevents renal function deterioration due to ischemia/reperfusion  Marilena Mister, Marina Noris, Jaroslaw Szymczuk, Nadia Azzollini, Sistiana Aiello, Mauro Abbate, Lech Trochimowicz, Elena Gagliardini, Arduino Arduini, Norberto Perico, Giuseppe Remuzzi  Kidney International  Volume 61, Issue 3, Pages 1064-1078 (March 2002) DOI: 10.1046/j.1523-1755.2002.00212.x Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 1 Experimental protocol. (A) Isolated perfused rat kidney (IPK). After equilibration (time 0) and a 10min. baseline period, kidneys were exposed to ischemia by reducing perfusion pressure to 10mm Hg. Perfusion pressure was then restored to normal (100mm Hg) and additional 9 consecutive 10-minute clearance periods were performed. Seven experimental groups were studied: group 1, IPK undergoing 20minutes of ischemia and infused with vehicle; group 2, IPK undergoing 20minutes of ischemia and infused with propionyl-l-carnitine from time 0; group 3, IPK undergoing 20minutes ischemia and infused with l-carnitine from time 0; group 4, control IPK not undergoing ischemia; group 5, IPK undergoing 40minutes of ischemia and infused with vehicle; group 6, IPK undergoing 40minutes of ischemia and infused with propionyl-l-carnitine from time 0; group 7, IPK undergoing 20minutes of ischemia and infused with propionyl-l-carnitine starting immediately after reperfusion (not shown in figure). (B) Syngeneic kidney transplant. Donor kidneys were transplanted in the syngeneic nephrectomized recipients after 4 hours of cold ischemia time in Belzer UW solution. Five experimental groups were studied: group 8, donor kidney transplanted after a 4-hour cold ischemia in Belzer plus vehicle; group 9, donor kidney transplanted after a 4-hour cold ischemia in Belzer plus propionyl-l-carnitine; group 10, donor kidney transplanted, no cold ischemia; group 11 (not shown), donor kidney transplanted after 4 hours of cold ischemia in Belzer plus vehicle, recipients sacrificed 16 hours post-transplantation; group 12, (not shown), donor kidney transplanted after 4 hours of cold ischemia in Belzer plus propionyl-l-carnitine, recipients sacrificed 16 hours after transplantation. Kidney International 2002 61, 1064-1078DOI: (10.1046/j.1523-1755.2002.00212.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 2 Effect of propionyl-L-carnitine on changes in glomerular filtration rate (GFR, A) and renal perfusate flow (RPF, B) induced by 20minutes of ischemia in an isolated perfused rat kidney preparation. Vehicle (○; N = 10), propionyl-l-carnitine (•; N = 10) or l-carnitine (□; N = 10) was infused into the renal artery starting before or immediately after the ischemic period. Values are mean ± SD. *P < 0.01 vs. propionyl-l-carnitine and baseline; P < 0.05 vs. baseline. Kidney International 2002 61, 1064-1078DOI: (10.1046/j.1523-1755.2002.00212.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 3 Tubular histological change score in control isolated perfused kidneys (IPKs; Control, N = 3), in kidney exposed to 20 or 40minutes of ischemia and treated with vehicle (Isch/reper + vehicle, N = 5), or propionyl-L-carnitine (Isch/reper + propionyl-L-carn nitine, N = 6). Symbols are: (□) TAL, thick ascending limbs; () PCT, proximal convoluted tubules. Values are mean ± SD. *P < 0.05 vs. Isch/reper + vehicle, §P < 0.05 vs. control and Isch/reper + propionyl-l-carn. Kidney International 2002 61, 1064-1078DOI: (10.1046/j.1523-1755.2002.00212.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 4 Histological appearance of fields of inner stripe (A, C, E) or outer stripe (B, D, F) of outer medulla of a control isolated perfused rat kidney (A, B), a kidney exposed to 20minutes of ischemia/reperfusion (C, D), and a kidney infused with propionyl-L-carnitine and exposed to 20minutes of ischemia/reperfusion (E, F) (H&E, ×500). Kidney International 2002 61, 1064-1078DOI: (10.1046/j.1523-1755.2002.00212.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 5 Representative photomicrograph of immunoperoxidase staining of outer medulla renal tissue with anti-4-HNE-lysine antibody. (A and B) Control IPK. (C and D) IPK undergoing 20minutes of ischemia and exposed to vehicle. (E and F) IPK exposed to propionyl-l-carnitine before ischemia. Original magnifications are ×100 (A, C, E) and ×400 (B, D, F). Kidney International 2002 61, 1064-1078DOI: (10.1046/j.1523-1755.2002.00212.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 6 Serum creatinine concentration in Lewis rat recipients of a syngeneic kidney pre-exposed to four hours of cold ischemia in Belzer UW solution (, N = 7) or in Belzer solution added with propionyl-L-carnitine (1.2 mg/mL, □, N = 7). Time 0 shows the serum creatinine concentration in the same animals before bilateral nephrectomy and transplantation. The gray bar represents the creatinine range in control recipients of a non-ischemic syngeneic kidney (N = 3). Values are mean ± SE. *P < 0.01, #P < 0.05 vs. ischemia untreated, P < 0.01 vs. control non-ischemic graft recipients. Kidney International 2002 61, 1064-1078DOI: (10.1046/j.1523-1755.2002.00212.x) Copyright © 2002 International Society of Nephrology Terms and Conditions

Figure 7 Immunohistochemical staining for infiltrating granulocytes in the glomeruli (intra- and periglomerular), the perivascular area and the interstitium of syngeneic kidneys transplanted after four hours of cold ischemia in Belzer (UW) solution (, N = 4) or in Belzer solution added to propionyl-L-carnitine (1.2 mg/mL, □,N = 4). All animals were studied 16 hours after transplantation. The number of cells was counted in at least 10 randomly selected high-power microscope fields (×400) for each animal. Values are mean ± SE. #P < 0.05 vs. ischemia untreated. Kidney International 2002 61, 1064-1078DOI: (10.1046/j.1523-1755.2002.00212.x) Copyright © 2002 International Society of Nephrology Terms and Conditions